SEC Form 4 · accession 0000905148-26-003836
Acrivon Therapeutics, Inc. · ACRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Peter Blume-Jensen
Officer — President and CEO · Director
Kristina Masson
Officer — EVP - Business Operations · Director
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 4:07 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001781174
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 18, 2026 | S | 1,229 | $2.01 | D | 2,244,088 | D | |
| Common StockF3 | Aug 18, 2026 | S | 484 | $2.01 | D | 385,859 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
- F2These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- F3These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.